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Abstract  41 
Objective: Testing for succinate dehydrogenase subunit B (SDHB) mutations is recommended in all 42 
patients with metastatic phaeochromocytomas and paragangliomas (PPGLs), but may not be required 43 
when metastatic disease is accompanied by adrenaline production. This retrospective cohort study 44 
aimed to establish the prevalence of SDHB mutations among patients with metastatic PPGLs 45 
characterised by production of adrenaline compared to those without production of adrenaline, and to 46 
establish genotype-phenotype features of metastatic PPGLs according to underlying gene mutations.  47 
Design & Methods: Presence of SDHB mutations or deletions was tested in 20 patients (114 males) 48 
aged 42±16 yrs (range 9 to 86 yrs) at diagnosis of metastatic PPGLs with and without adrenaline 49 
production.  50 
Results: Twenty-three of the 205 patients (11%) with metastatic PPGLs had disease characterized by 51 
production of adrenaline, as defined by increased plasma concentrations of metanephrine larger than 52 
5% of the combined increase of both normetanephrine and metanephrine. None of these 23 patients 53 
had SDHB mutations. Of the other 182 patients with no tumoural adrenaline production, 51% had 54 
SDHB mutations. Metastases in bone were 36% to 41% more prevalent among patients with SDHB 55 
mutations or extra-adrenal primary tumours than those without mutations or with adrenal primary 56 
tumours. Liver metastases were 81% more prevalent among patients with adrenal than extra-adrenal 57 
primary tumours.  58 
Conclusion: SDHB mutation testing has no utility among patients with adrenaline-producing 59 
metastatic PPGLs, but is indicated in other patients with metastatic disease. Our study also reveals 60 
novel associations of metastatic spread with primary tumour location and presence of SDHB 61 
mutations. 62 
63 
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Introduction 64 
Phaeochromocytomas and paragangliomas (PPGLs) are catecholamine-producing tumours that 65 
respectively arise from adrenal medullary or paraganglial chromaffin cells (1, 2). Over 30% of PPGLs 66 
have a hereditary basis due to mutations of more than 11 tumour-susceptibility genes identified to 67 
date (3, 4). In a significant proportion of cases mutations are found without any clear family history or 68 
syndromic features suggesting a hereditary basis (5-10). Identification of mutations in such patients is 69 
important since this impacts subsequent patient management. Mutation testing can also lead to 70 
identification of other family members with the same mutation, who are at risk for PPGLs and other 71 
tumours and who can benefit from routine screening to identify disease at an early stage.  72 
Due to the above considerations, it has been suggested that all patients with PPGLs should undergo 73 
testing for germline mutations of tumour susceptibility genes regardless of family history or 74 
syndromic features (5). Although costs of mutation testing may be significantly reduced with next 75 
generation sequencing, currently the testing of all genes in every patient with PPGLs is costly and not 76 
recommended (11, 12). Rather the decision to test and selection of genes to be tested should be based 77 
on genotype-phenotype considerations (9, 11, 12). High risk of metastatic disease in patients with 78 
mutations of the succinate dehydrogenase subunit B (SDHB) gene (7), leading to high prevalence of 79 
SDHB mutations in patients with metastatic PPGLs (13), has in particular led to agreement that all 80 
patients with metastatic PPGLs should be considered for testing of that gene (6, 7, 9, 11). This 81 
recommendation is now supported by Endocrine Society Guidelines on PPGLs  (12).  82 
PPGLs in patients with SDHB mutations are characterised by production of noradrenaline and/or 83 
dopamine, without significant production of adrenaline (14). This suggests that testing for SDHB 84 
mutations may not be required if metastatic disease is associated with significant adrenaline 85 
production. There are, however, limited data concerning biochemical phenotypic features in 86 
metastatic PPGLs according to SDHB mutation status. Consequently, as indicated by the recently 87 
published guidelines (12), recommended testing of SDHB mutations in patients with malignant 88 
PPGLs remains independent of any consideration concerning biochemical phenotypes.  89 
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The primary objective of this study was therefore to establish the prevalence of SDHB mutations 90 
among patients with metastatic PPGLs with and without adrenaline production. Secondary objectives 91 
included characterisation of other phenotypic features in patients with metastatic PPGLs according to 92 
SDHB mutation status and primary tumour location. 93 
 94 
Patients and Methods 95 
Patients  96 
The study involved retrospective analysis of data from 205 patients with metastatic PPGLs diagnosed 97 
on imaging evidence of metastatic disease combined with either or both a past history of 98 
pathologically proven PPGLs or biochemical evidence of excess catecholamine production. Imaging 99 
evidence of metastatic lesions at sites where chromaffin cells are normally absent involved a 100 
combination of computed tomography or magnetic resonance imaging with one or more of several 101 
functional imaging modalities: 123I-metaiodobenzylguanidine scintigraphy, 68Ga-DOTATATE 102 
positron emission tomography (PET), 18F-fluoro-2-deoxy-D-glucose PET, 18F-3,4-103 
dihydroxyphenylalanine PET, and 18F-fluorodopamine PET. Patients were investigated at the National 104 
Institutes of Health or at seven European centres under the multicentre prospective monoamine-105 
producing tumour protocol (https://pmt-study.pressor.org/jsp/home.jsp). Written informed consent 106 
was obtained from all patients.  107 
 108 
Inclusion criteria and data collection 109 
Apart from presence of metastases at locations where chromaffin cells are normally absent (e.g., 110 
bones, lungs, liver, lymph nodes), consecutive inclusion of patients into the analysis required two key 111 
criteria: 1. chromatography-based measurements of plasma concentrations of normetanephrine and 112 
metanephrine performed on blood samples taken when metastatic disease was present; and 2. 113 
assessment for presence of SDHB mutations determined by Sanger sequencing and multiplex ligation-114 
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dependent probe amplification (MLPA). The latter was commonly performed using the p226 SDH kit 115 
from MRC-Holland (Amsterdam, The Netherlands). 116 
Other required data were restricted to gender, date of birth, date of first diagnosis of primary tumours 117 
and metastatic disease and locations of primary tumours and metastases. Dimensions of primary 118 
tumours were available from 176 of the 205 patients. In line with current recommendations, testing of 119 
tumour susceptibility genes other than SDHB was not routinely performed unless indicated by disease 120 
presentation or other considerations. 121 
 122 
Definition of adrenaline-producing PPGLs  123 
As described previously (15), adrenaline-producing tumours were defined by both increased plasma 124 
concentrations of metanephrine above the upper cut-offs (88 pg/mL, 0.45 nmol/L) and increases of 125 
metanephrine larger than 5% of the combined increases of both plasma normetanephrine and 126 
metanephrine. The latter was defined by the equation  %MNt = (MNt/NMNt+MNt).100 where MNt 127 
and NMNt are tumour-derived plasma concentrations of metanephrine and normetanephrine. As 128 
described previously (15), tumour-derived concentrations were determined by subtracting mean 129 
concentrations in a reference population of patients without PPGLs from measured concentrations in 130 
patients with PPGLs. 131 
 132 
Statistics   133 
Statistical analysis was performed using JMP Pro10 (10.0.1.1), with significance established by Chi-134 
squared, Wilcoxon, Kruskal-Wallis, Steel-Dwass nonparametric multiple comparison nominal logistic 135 
multivariate tests as appropriate. Principal components analysis was carried out for 3 principal 136 
components defining tumoural adrenaline production that clustered data in 3 dimensional space 137 
separately.  138 
    139 
 140 
141 
Page 7 of 23
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
 7 
Results  142 
The 205 patients with metastatic PPGLs (114 males) were aged 36±16 yrs (range 6-83 yrs) at initial 143 
diagnosis of PPGLs and 42±16 yrs at diagnosis of metastatic disease (range 9-86 yrs). Sixty-three 144 
patients (31%) had primary tumours at adrenal locations, 132 (64%) at extra-adrenal locations and 10 145 
(5%) at both locations with multifocal tumours. Metastases in bones, liver, lungs and lymph nodes 146 
were respectively identified in 75%, 40%, 36% and 56% of patients, mostly showing multiple 147 
locations. Ninety-three of the 205 patients with metastatic PPGLs (45%) harboured SDHB mutations 148 
(Supplemental Table). Mutation testing, when clinically indicated among the other 112 patients, 149 
revealed mutations of subunit D of succinate dehydrogenase (SDHD) in 13 patients, subunit A of 150 
succinate dehydrogenase (SDHA) in 1 patient, the von Hippel-Lindau gene in 5 patients and the RET 151 
(rearranged during transfection) gene in 5 patients.  152 
Among all 205 patients, 30 patients presented with elevations of metanephrine (Fig 1). Among these 153 
30 patients, 23 had increases of tumour-derived metanephrine higher than 5% of the combined 154 
increases of both normetanephrine and metanephrine, defining these patients as adrenaline-producing 155 
metastatic PPGLs. The other 7 patients with elevations of metanephrine had much larger elevations in 156 
normetanephrine, so that this did not reach the 5% criterion for defining significant adrenaline 157 
production. The twenty-three patients (11%) with adrenaline-producing metastatic PPGLs, none of 158 
who had SDHB gene mutations, were clearly distinguished from all other patients. Thus, of the other 159 
182 patients with no tumoural adrenaline production, a higher proportion of 93 patients had SDHB 160 
mutations compared to those exhibiting an adrenaline-producing phenotype (51 % vs. 0% P<0.0001) 161 
(Table 1). Twenty-two of the 23 patients with an adrenergic biochemical phenotype had primary 162 
tumours localised to the adrenals, a higher proportion (P<0.0001) than for patients with metastatic 163 
PPGLs without adrenaline production (96% vs. 28%). Adrenergic metastatic disease was 164 
characterised by 27-fold higher (P<0.0001) plasma concentrations of metanephrine compared to 165 
disease without adrenaline production. No differences in locations of metastases were apparent 166 
according to differences in catecholamine biochemical phenotypes. 167 
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Patients with SDHB gene mutations were on average 9 and 11 years younger at respective diagnosis 168 
of primary tumours and metastatic disease compared to those without SDHB mutations (Table 2). 169 
Twenty-three of 34 paediatric patients diagnosed with primary tumours before reaching 18 years 170 
(range 6-18 yrs) had SDHB mutations, a higher proportion than the 70 of 171 adult cases with SDHB 171 
gene mutations (68% vs. 41%, P= 0.0043). Male gender was more prevalent among patients with 172 
SDHB gene mutations compared to those without SDHB gene mutations (65% vs. 48%, P=0.0193). 173 
This difference reflected 17 of 20 paediatric male patients who had SDHB gene mutations compared 174 
to 43 of 94 adult male patients with SDHB gene mutations (85% vs. 46%, P=0.0016).  175 
Metastatic disease secondary to adrenal phaeochromocytomas was associated with a higher 176 
(P<0.0001) proportion of adrenergic phenotypic features and a lower proportion (P<0.0001) of SDHB 177 
mutations than disease secondary to extra-adrenal paragangliomas (Table 3). Age at first diagnosis of 178 
primary tumours and metastatic disease was higher (P<0.001) for patients with adrenal than extra-179 
adrenal primary tumours. Thirty-four paediatric patients were characterised by a higher (P=0.0087) 180 
prevalence of tumours at extra-adrenal and multifocal adrenal and extra-adrenal locations (88%) 181 
compared to adults (65%).  182 
Patients with SDHB mutations showed a 36% higher (P=0.0002) prevalence of metastases in bone 183 
compared to those without SDHB mutations (Table 2). There was also a 41% higher (P=0.0006) 184 
prevalence of bone metastases among patients with extra-adrenal than adrenal primary tumours, 185 
whereas liver metastases were 81% more prevalent (P<0.001) among patients with adrenal than extra-186 
adrenal primary tumours (Table 3). Multivariate analysis (with SDHB mutation status, tumour 187 
location and catecholamine biochemical phenotype as independent variables) indicated that for bone 188 
metastases SDHB gene mutation status (P=0.0145), and location of primary tumours (P=0.0370), but 189 
not catecholamine phenotype (P=0.7902) remained the critical determinants. Similarly, location of the 190 
primary tumour remained the only significant (P=0.0041) determinant for liver metastases when both 191 
SDHB mutation status (P=0.9655) and catecholamine biochemical phenotype (P=0.6093) were 192 
considered as additional variables by multivariate analysis.  193 
194 
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Discussion 195 
This study, involving one of the largest cohorts of patients with metastatic PPGLs yet described, 196 
establishes adrenergic phenotype-related differences in disease-causing SDHB mutations, not only 197 
relevant to testing of the gene, but also to interpretation and follow-up of test results. The study also 198 
provides confirmatory evidence for relationships between presence of SDHB mutations, tumour 199 
location and differences in ages and gender of disease presentation, but importantly presents novel 200 
findings relating the former two variables to occurrence of metastasis at different locations.  201 
The testing of every tumour-susceptibility gene in every PPGL patient is not supported by any 202 
published evidence to date relating cost-effectiveness to clinical outcome (11, 12). Nevertheless, the 203 
high prevalence of SDHB mutations among patients with metastatic PPGLs leaves little doubt that 204 
targeted SDHB testing is warranted for this presentation (6, 7, 9, 11-13). Findings of an SDHB 205 
mutation in such patients may be particularly important for identification of other family members 206 
with mutations who may benefit from routine screening and therapeutic interventions at an early stage 207 
before metastasis occurs.  208 
As we now show here, complete lack of SDHB mutations among 23 patients with metastatic PPGLs 209 
characterised by adrenergic biochemical features indicates that testing of the SDHB gene is of no 210 
benefit when disease is associated with significant production of adrenaline, as indicated by increases 211 
in plasma metanephrine.  Guidelines for SDHB testing, such as those recently published by the 212 
Endocrine Society (12), should thus be modified to exclude testing when disease is accompanied by 213 
increases in metanephrine. For those patients presenting with adrenaline-producing metastatic PPGLs, 214 
testing for RET, MAX, TMEM127 or NF1 gene mutations could be considered. However, we would 215 
not recommend such testing unless patients present with a family history consistent with hereditary 216 
PPGLs, evidence of syndromic features, young age or bilateral adrenal tumours.  217 
The above considerations and recommendations are consistent with current guidelines that genetic 218 
testing should be prioritised according to clinical features, with specific genes targeted according to 219 
those features (12). As also outlined in those guidelines such selective approaches to genetic testing 220 
Page 10 of 23
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
 10
may be become obsolete with introduction of next-generation sequencing (NGS) methods that allow 221 
rapid and low-cost analysis of all PPGLs susceptibility genes. Nevertheless, whether NGS should be 222 
applied indiscriminately to all patients with PPGLs, including those with adrenaline-producing 223 
metastatic tumours, requires evidence from carefully designed prospective outcome studies clearly 224 
establishing that benefits to patients and their families outweigh costs and potential harms. Such 225 
harms include wrongful designation of non-functional polymorphisms as pathogenic mutations. As 226 
outlined elsewhere (16) this problem is likely to become highly relevant with NGS, for which 227 
interpretation of pathogenicity among detected variants of unknown significance can be a major 228 
challenge. Such problems have already surfaced in several case reports of test results in patients with 229 
PPGLs initially interpreted to indicate a mutation, but subsequently determined to reflect a non-230 
pathogenic variant (17, 18). In such cases biochemical findings that do not fit the genotype can 231 
provide useful information to review relative to potential pathogenicity before any subsequent actions 232 
may adversely affect patients or their family. 233 
The 23 patients in the present study with adrenaline-producing malignant PPGLs included one case 234 
with a retroperitoneal paravertebral extra-adrenal tumour. Extra-adrenal paragangliomas very rarely 235 
produce significant amounts of adrenaline. This patient therefore represents an exception to the rule 236 
and it is important to note that all 22 of the other cases of adrenaline-producing metastatic PPGLs 237 
included patients with adrenal primary tumours. From this it might be surmised that patients with 238 
metastatic PPGLs due to adrenal primary tumours might also not benefit from testing for SDHB 239 
mutations. Indeed, while the prevalence of SDHB mutations among patients with primary tumours 240 
localized to the adrenals is much lower than that for patients with extra-adrenal tumours (13% vs. 241 
62%), it is nevertheless the presence or absence of adrenaline production that better defines likelihood 242 
of an underlying SDHB mutation. 243 
Our findings of associations of SDHB mutations with extra-adrenal locations of primary tumours and 244 
young age at diagnosis are in agreement with several previous studies (5-7, 9-11, 13, 19). Bausch et 245 
al. showed SDHB gene mutations were highly prevalent among paediatric patients with hereditary and 246 
malignant disease (20). Higher prevalence of SDHB mutations in children than in adults with 247 
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metastatic disease is also consistent with other findings in a paediatric series establishing a high 248 
proportion of cases with SDHB mutations and metastatic disease, (21); it was concluded that testing 249 
for SDHB mutations and follow-up to check for metastasis is particularly important in paediatric cases 250 
of PPGLs. We extend these findings by now showing that male gender is more prevalent among 251 
paediatric than adult patients with SDHB mutations who develop metastatic PPGLs. Male gender has 252 
been previously described by Neumann et al. (22) as an independent risk factor for SDHx germline 253 
mutations among patients with head and neck paragangliomas, but the basis of this observation and 254 
how it relates to the present findings are not established.   255 
The higher prevalence of bone metastasis in patients with SDHB mutations compared to those without 256 
SDHB mutations represents novel unexpected findings. The higher prevalence of liver metastasis 257 
associated with adrenal than extra-adrenal tumours and the reverse higher prevalence of bone 258 
metastasis associated with extra-adrenal compared to adrenal tumours represent other novel findings. 259 
By multivariate analysis we show that the catecholamine biochemical phenotype appears irrelevant to 260 
these differences in metastatic spread. It remains unclear why the presence of an SDHB mutation or 261 
extra-adrenal tumour predisposes to bone metastasis whereas presence of an adrenal primary tumour 262 
predisposes to liver metastasis. 263 
In summary, lack of SDHB mutations among patients with adrenaline-producing metastatic PPGLs 264 
indicates that it is unnecessary to test for SDHB mutations among such patients. High prevalence of 265 
SDHB mutations among other patients with metastatic PPGLs supports recommendations that these 266 
patients should all be considered for SDHB mutation testing. Our data also indicate associations of 267 
metastatic spread with primary tumour location and presence of SDHB mutations.  268 
269 
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Figure Legend 282 
Figure 1. 283 
Principal components analysis 3 dimensional scatter plot illustrating clustering of patients with 284 
metastatic PPGLs according to presence or absence of tumoural adrenaline production and SDHB 285 
gene mutations. Values shown on the axis are in log scale, whereas values of metanephrine and 286 
normetanephrine are in units of nanomoles per litre. %MNt is defined as the increase of tumour-287 
derived plasma metanephrine as a per cent of both normetanephrine and metanephrine as described in 288 
methods. Patients with tumours producing adrenaline are indicated by triangles, whereas patients with 289 
tumours without adrenaline production are indicated by dots or circles, with patients with SDHB 290 
mutations are shown by circles, and those without SDHB mutations are shown by dots or triangles.  291 
292 
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TABLE 1. Disease-associated characteristics of metastatic PPGLs 
according to production or lack of production of adrenaline. 
      
    Adrenaline production 
No 
Adrenaline 
production 
P value 
N   23 182  
Male gender 8 (35%) 106 (58%) 0.0329 
SDHB mutation 0 (0%) 93 (51%) <0.0001 
Adrenal primary tumour* 22 (96%) 51 (28%) <0.0001 
Primary tumour volume (mL)† 178±56 132±20 0.1812 
Age at first diagnosis (yrs)§ 39±12 35±16 0.2316 
Age at metastasis (yrs)§ 48±13 41±16 0.0664 
Plasma MN (nmol/L)† 5.3±1.1 0.2±0.1 <0.0001 
Plasma NMN (nmol/L)† 14.0±3.7 11.3±1.6 0.0079 
Location of metastases    
  Bone 14 (61%) 139 (77%) 0.1074 
  Liver 12 (52%) 70 (38%) 0.2059 
  Lungs 6 (26%) 67 (37%) 0.3114 
  Lymph nodes 12 (52%) 102 (56%) 0.7249 
Abbreviations: mL, milliliter; nmol/L, nanomoles per litre; MN, metanephrine; 
NMN, normetanephrine. *Primary tumors designated with an adrenal location 
include 10 with multifocal adrenal and extra-adrenal locations; † means±SE; § 
means±SD. 
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TABLE 2. Disease-associated characteristics of metastatic PPGLs 
according to presence or absence of SDHB mutations.  
      
    SDHB mutation 
No SDHB 
mutation P value 
N   93 112  
Male gender 60 (65%) 54 (48%) 0.0193 
Adrenergic disease 0 (0%) 23 (21%) <0.0001 
Adrenal primary tumour* 11 (12%) 62 (55%) <0.0001 
Primary tumour volume (mL)† 131±20 142±29 0.1548 
Age at first diagnosis (yrs)§ 31±15 40±16 <0.0001 
Age at metastasis (yrs)§ 36±14 47±15 <0.0001 
Plasma MN (nmol/L)† 0.2±0.1 1.3±0.3 0.0008 
Plasma NMN (nmol/L)† 14.0±2.6 9.6±1.7 0.7140 
Location of metastases    
  Bone 81 (87%) 72 (64%) 0.0002 
  Liver 32 (34%) 50 (45%) 0.1365 
  Lungs 30 (32%) 43 (39%) 0.3611 
  Lymph nodes 52 (56%) 62 (55%) 0.9363 
Abbreviations: mL, milliliter; nmol/L, nanomoles per litre; MN, 
metanephrine; NMN, normetanephrine. *Primary tumors designated with 
an adrenal location include 10 with multifocal adrenal and extra-adrenal 
locations; † means±SE; § means±SD. 
 2 
Page 22 of 23
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
 1 
 1 
TABLE 3. Disease-associated characteristics of metastatic PPGLs according to 
adrenal and extra-adrenal locations of primary tumors. 
      
    Adrenal Extra-Adrenal 
Adrenal & 
extra-
adrenal 
P value* 
N  63 132 10  
Male gender 28 (44%) 80 (61%) 6 (60%) 0.1005 
Adrenergic phenotype 21 (33%)*** 1 (1%) 1 (10%) <0.0001 
SDHB mutation 8 (13%)*** 82 (62%) 3 (30%) <0.0001 
Primary tumour volume (mL)† 195±46 105±15 193±405 0.3374 
Age at first diagnosis (yrs)§ 43±16*** 33±15 31±21 0.0003 
Age at metastasis (yrs)§ 50±13*** 38±15 37±20 <0.0001 
Plasma MN (nmol/L)† 2.0±0.5 0.2±0.1 0.4±0.3 0.0676 
Plasma NMN (nmol/L)† 14.3±3.2** 10.7±1.8 5.8±2.0 0.0052 
Location of metastases     
 Bone 37 (59%)*** 110 (83%) 6 (60%) 0.0006 
 Liver 35 (56%)*** 41 (31%) 6 (60%) 0.0020 
 Lungs 24 (38%) 43 (33%) 6 (60%) 0.1926 
  Lymph nodes 36 (57%) 72 (55%) 6 (60%) 0.9055 
Abbreviations: mL, milliliter; nmol/L, nanomoles per litre; MN, metanephrine; NMN, 
normetanephrine. *P value indicates overall significance by Kruskal-Wallis multiple 
comparison tests. ** and *** designates significant difference (P<0.01) and (P<0.001) 
from extra-adrenal group by post hoc testing; † means±SE; § means±SD. 
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Supplemental Table 1. Germline mutations of SDHB identified among malignant PPGLs patients. 
Exon / 
intron 
Mutation cDNA 
nucleotide change 
Mutation protein 
change Coding effect 
Number 
of cases 
1 to 8 c.1-c.843del Exon 1-8 Deletion Whole Gene Deletion 3 
1 c.1A>T p.Met1? Start Loss 1 
1 c.1_72del Exon 1 Deletion Deletion 6 
1 c.26T>A p.Leu9* Nonsense mutation 1 
IVS1 c.72+1G>T Splice site mutation Splice site mutation 8 
IVS1 c.73-9A>G (IVS1-9A>G) Splice site mutation Splice site mutation 1 
2 c.136C>T p.Arg46* Nonsense mutation 8 
2 c.137G>A p.Arg46Gln Missense mutation 3 
3 c.268C>T p.Arg90* Nonsense mutation 4 
3 c.271A>T p.Arg91* Nonsense mutation 1 
3 c.274T>C p.Ser92Pro Missense mutation 1 
3 c.275C>A p.Ser92* Nonsense mutation 1 
3 c.277T>C p.Cys93Arg Missense mutation 1 
IVS3 c.286+1G>A Splice site mutation Splice site mutation 2 
IVS3 c.286+2T>A Splice site mutation Splice site mutation 3 
IVS3 c.287-1G>C Splice site mutation Splice site mutation 1 
4 c.287G>A p.Gly96Asp Missense mutation 1 
4 c.330delTC p.Leu111Serfs*7 Frameshift mutation 1 
4 c.343C>T p.Arg115* Nonsense mutation 1 
4 c.369_370insA p.Val124Serfs*39 Frameshift mutation 1 
4 c.380T>G p.Ile127Ser Missense mutation 6 
4 c.392delC p.Pro131Hisfs*5 Frameshift mutation 1 
4 c.395A>C p.His132Pro missense mutation 1 
4 c.418G>T p.Val140Phe Missense mutation 7 
IVS4 c.423+1G>A Splice site mutation Splice site mutation 2 
5 c.445-447delCAinsGGTATCT p.Gln149Glyfs*11 Frameshift mutation 1 
5 c.445C>T p.Gln149* Nonsense mutation 1 
IVS5 c.541-2A>G(IVS5-2A>G) Splice site mutation Splice site mutation 2 
6 c.553G>T p.Glu185* Nonsense mutation 1 
6 c.574T>C p.Cys192Arg Missense mutation 2 
6 c.587G>A p.Cys196Tyr Missense mutation 3 
6 c.590C>G p.Pro197Arg Missense mutation 1 
6 c.600G>T p.Trp200Cys Missense mutation 1 
6 c.626C>T p.Pro209Leu Missense mutation 1 
6 c.642G>C p.Gln214His Missense mutation 1 
IVS6 c.642+1G>A Splice site mutation Splice site mutation 3 
7 c.683_684delAG p.Glu228Glyfs*27 Frameshift mutation 1 
7 c.688C>T p.Arg230Cys Missense mutation 2 
7 c.689G>A p.Arg230His Missense mutation 2 
7 c.689G>T p.Arg230Leu Missense mutation 2 
7 c.725G>A p.Arg242His Missense mutation 1 
7 c.727T>A p.Cys243Ser Missense mutation 1 
7 c.761dup p.Lys255* Frameshift mutation 1 
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